IndexIQ Advisors LLC purchased a new stake in shares of C.R. Bard, Inc. (NYSE:BCR) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 67,020 shares of the medical instruments supplier’s stock, valued at approximately $21,186,000. C.R. Bard accounts for approximately 1.0% of IndexIQ Advisors LLC’s portfolio, making the stock its 24th largest position. IndexIQ Advisors LLC owned about 0.09% of C.R. Bard as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in BCR. Macquarie Group Ltd. increased its position in shares of C.R. Bard by 61.1% in the fourth quarter. Macquarie Group Ltd. now owns 5,800 shares of the medical instruments supplier’s stock valued at $1,303,000 after buying an additional 2,200 shares during the last quarter. Candriam Luxembourg S.C.A. increased its position in shares of C.R. Bard by 31.2% in the first quarter. Candriam Luxembourg S.C.A. now owns 5,262 shares of the medical instruments supplier’s stock valued at $1,308,000 after buying an additional 1,252 shares during the last quarter. Profund Advisors LLC increased its position in shares of C.R. Bard by 13.1% in the first quarter. Profund Advisors LLC now owns 2,915 shares of the medical instruments supplier’s stock valued at $724,000 after buying an additional 338 shares during the last quarter. Glen Harbor Capital Management LLC increased its position in shares of C.R. Bard by 4.7% in the first quarter. Glen Harbor Capital Management LLC now owns 3,184 shares of the medical instruments supplier’s stock valued at $791,000 after buying an additional 144 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its position in shares of C.R. Bard by 7.3% in the first quarter. Janney Montgomery Scott LLC now owns 3,546 shares of the medical instruments supplier’s stock valued at $881,000 after buying an additional 241 shares during the last quarter. 79.32% of the stock is owned by hedge funds and other institutional investors.

C.R. Bard, Inc. (BCR) traded down 0.09% during mid-day trading on Tuesday, hitting $319.23. 8,375 shares of the stock were exchanged. The company has a 50-day moving average of $319.82 and a 200-day moving average of $289.48. The stock has a market capitalization of $23.20 billion, a PE ratio of 41.91 and a beta of 0.59. C.R. Bard, Inc. has a 52 week low of $203.63 and a 52 week high of $323.27.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, topping the consensus estimate of $2.84 by $0.08. The company had revenue of $979.70 million during the quarter, compared to analyst estimates of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.54 EPS. On average, equities analysts predict that C.R. Bard, Inc. will post $11.82 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were issued a $0.26 dividend. This represents a $1.04 annualized dividend and a yield of 0.33%. The ex-dividend date of this dividend was Thursday, July 20th. C.R. Bard’s payout ratio is presently 13.67%.

COPYRIGHT VIOLATION NOTICE: “IndexIQ Advisors LLC Purchases Shares of 67,020 C.R. Bard, Inc. (BCR)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/29/indexiq-advisors-llc-purchases-shares-of-67020-c-r-bard-inc-bcr.html.

Several research analysts have commented on BCR shares. Zacks Investment Research raised shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $342.00 price target for the company in a report on Thursday, May 11th. BidaskClub raised shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 8th. Finally, BMO Capital Markets reissued a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $285.67.

In other news, insider John P. Groetelaars sold 23,687 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the sale, the insider now owns 31,445 shares of the company’s stock, valued at $10,022,464.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.80% of the stock is currently owned by insiders.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.